Monte Rosa Therapeutics
Develops molecular glue degrader medicines across oncology, immunology, and inflammation.
Something off on this page? Send us feedback.
Profile
Builds small-molecule degraders using the QuEEN discovery engine, with clinical programs in oncology, immunology, inflammation, and cardiometabolic disease. The business is pre-commercial, with collaboration revenue from Roche and Novartis rather than approved product sales.
Uses the QuEEN discovery engine to design molecular glue degraders, small-molecule medicines that direct disease-relevant proteins toward cellular degradation. Current named programs include MRT-2359 in oncology, MRT-6160 for immune-mediated disease through Novartis, and MRT-8102 for inflammatory and cardiometabolic settings.
Runs research from Boston and Basel, with a research-heavy workforce and clinical-stage development model. Collaboration agreements with Roche and Novartis provide current revenue while wholly owned and partnered programs advance through trials.
Execution depends on clinical data, regulatory progress, partner activity, and continued financing capacity. No approved product revenue was disclosed in the business materials opened for context.
Company facts
Key statistics
Year to date −12.6% · Average volume (30d) 1.4M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 7, 2026 | Guggenheim | Reiterate | Buy | $35 | $28 | |
| Aug 3, 2026 | Wedbush | Reiterate | Outperform | $37 | $27 | |
| Jul 31, 2026 | Jefferies | Target | $40 | $25 | ||
| Jul 27, 2026 | Jefferies | Reiterate | Buy | $31 | $40 | |
| Jun 30, 2026 | Guggenheim | Reiterate | Buy | $35 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026Q2 FY26 | −$0.38 | −$0.43 | −13.0% | $12.9M | $9.0M | −30.3% | +0.64% |
| May 7, 2026Q1 FY26 | −$0.28 | −$0.45 | −60.7% | $11.0M | $4.2M | −61.7% | −2.12% |
| Mar 17, 2026Q4 FY25 | −$0.35 | −$0.54 | −53.6% | $15.6M | $2.8M | −82.0% | −1.68% |
| Nov 6, 2025Q3 FY25 | −$0.37 | −$0.33 | +9.9% | $15.5M | $12.8M | −17.7% | −5.38% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $84.9M | $23.2M | $12.8M | $2.8M | $4.2M | $9.0M | |
| Gross profit | $84.9M | $23.2M | $12.8M | $2.8M | $2.2M | $9.0M | |
| Operating income | $44.0M | −$15.6M | −$33.0M | −$49.7M | −$50.0M | −$49.1M | |
| Net income | $46.9M | −$12.3M | −$27.1M | −$46.1M | −$44.5M | −$43.4M | |
| Diluted EPS | $0.57 | −$0.20 | −$0.44 | −$0.70 | −$0.53 | −$0.51 | |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 51.8% | 100.0% | |
| Operating margin | 51.9% | -67.1% | -258.3% | -1,787.7% | -1,188.5% | -547.8% |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $0 · FY24 $75.6M · FY25 $123.7M
Balance sheet, Jun 30, 2026Cash & short-term investments $621.1M · Total debt $38.0M · Total assets $696.1M · Shareholders' equity $487.3M
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 84.48M · Float 59.76M · 70.7% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Price T Rowe Associates Inc /MD/ | 8.86M | 10.49% | 13F | Aug 14, 2026 |
| Nea Management Company, LLC | 7.69M | 9.11% | 13F | Aug 14, 2026 |
| BlackRock, Inc. | 6.84M | 8.10% | 13F | Aug 7, 2026 |
| Nea 17 GP, LLC | 6.69M | 7.90% | 13D | Jul 6, 2026 |
| Adam Goulburn | 6.51M | 8.10% | 13G | Apr 22, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 16, 2026 | Markus Warmuth | director, officer: President & CEO | −9,500 | $23.18 |
| Jul 15, 2026 | Jennifer Champoux | officer: Chief Operating Officer | −4,351 | $23.38 |
| Jul 6, 2026 | Sharon Townson | officer: Chief Scientific Officer | −6,000 | $23.31 |
| Jun 30, 2026 | Filip Janku | officer: Chief Medical Officer | −5,407 | $24.50 |
| Jun 29, 2026 | Anthony M. Manning | director | −10,000 | $23.11 |
Peers
- Kymera Therapeutics
Closest public TPD peer in immunology and molecular glues
- Nurix Therapeutics
TPD platform peer across oncology and autoimmune programs
- C4 Therapeutics
Public TPD specialist with clinical oncology degraders
- Bristol-Myers Squibb
Large pharma leader in CELMoD and TPD medicines
- Novartis (ADR)
Global pharma TPD participant and key immunology partner
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Monte Rosa Therapeutics | $13.38 | +0.04% | $1.13B | — | — | 39.3 | −61.2% |
| Kymera Therapeutics | $118.15 | +0.06% | $9.72B | — | — | 92.6 | +466.4% |
| Nurix Therapeutics | $26.64 | +1.72% | $2.72B | — | — | 74.0 | −79.5% |
| C4 Therapeutics | $3.91 | +1.54% | $425.7M | — | — | 12.1 | +2.8% |
| Bristol-Myers Squibb | $66.60 | +0.05% | $136.00B | 14.7 | 10.5 | 2.8 | +5.7% |
| Novartis (ADR) | $153.81 | 0.00% | $292.35B | 23.2 | 16.4 | 5.3 | +0.9% |
| Median | 18.9 | 13.4 | 12.1 | +2.8% |